CD200 - Revision history

John at 19:47, 4 July 2023

2023-07-04T19:47:32Z

← Older revision		Revision as of 21:47, 4 July 2023
Line 57:		Line 57:
	{\| class=wikitable style="text-align: center; font-size:80%; width: 100%; height 20px;"		{\| class=wikitable style="text-align: center; font-size:80%; width: 100%; height 20px;"
	\|-		\|-
	!colspan="8"\|'''Expression: mature B cell neoplasms'''		!colspan="8"\|'''Expression in mature B cell neoplasms'''
	\|-		\|- <span style="font-size:70%">
	! CLL !! MCL !!FL!! MZL !! HCL !! DLBCL \|\| LPL !! PCL		! CLL !! MCL !!FL!! MZL !! HCL !! DLBCL \|\| LPL !! PCL
	\|-		\|-<span style="font-size:70%">
	\|style="width: 12.5%; background: #004466; color:white"\|80-100%		\|style="width: 12.5%; background: #004466; color:white"\|80-100%
	\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%		\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%

John at 11:24, 3 July 2023

2023-07-03T11:24:34Z

← Older revision		Revision as of 13:24, 3 July 2023
Line 53:		Line 53:
	\|-		\|-
	\|}		\|}


	<span style="font-size:90%">'''Notes:''' The main application is in AML. Aberrant expression is seen in ALL particularly in T-lineage, although it may be less likely in Burkitt lymphoma. CD117 expression can indicate MPAL or ETP-ALL if other markers are consistent.

John at 11:22, 3 July 2023

2023-07-03T11:22:50Z

← Older revision		Revision as of 13:22, 3 July 2023
Line 44:		Line 44:
	\|-<span style="font-size:70%">		\|-<span style="font-size:70%">
	\|style="width: 12.5%; background: #006699; color:white"\|40-80%		\|style="width: 12.5%; background: #006699; color:white"\|40-80%
	\|style="width: 12.5%; background: #~~E6FAFF~~; color:black"\|20-40%		\|style="width: 12.5%; background: #00b8e6; color:black"\|20-40%
	\|style="width: 12.5%; background: #004466; color:white"\|80-100%		\|style="width: 12.5%; background: #004466; color:white"\|80-100%
	\|style="width: 12.5%; background: #004466; color:white"\|80-100%		\|style="width: 12.5%; background: #004466; color:white"\|80-100%

John at 11:22, 3 July 2023

2023-07-03T11:22:21Z

← Older revision		Revision as of 13:22, 3 July 2023
Line 37:		Line 37:


	{\| class=wikitable style="text-align: center; font-size:80%; width: ~~87.5~~%; height 20px;"		{\| class=wikitable style="text-align: center; font-size:80%; width: 100%; height 20px;"
	\|-
	~~!colspan="7"\|<span style="font-size:100%">'''Expression: primitive cell types''' ''Click (i) on table for additional information'' </span></font>~~
	\|-
	~~! AML !! B ALL !! Burkitt \|\| T ALL !! ETP ALL ('''[[Early T Precursor ALL (ETP-ALL)\|i]]''') !! MPAL ('''[[Mixed Phenotype Acute Leukaemia (MPAL)\|i]]) \|\| H.gones ('''[[Haematogones\|i]]''')~~
	\|-		\|-
			!colspan="8"\|'''Expression in primitive cell types'''</font>
			\|- <span style="font-size:70%">
			!AML!!CMML !!B ALL !!BL \|\|T ALL !!ETP ALL !!MPAL \|\|Hgn</span>
			\|-<span style="font-size:70%">
	\|style="width: 12.5%; background: #006699; color:white"\|40-80%		\|style="width: 12.5%; background: #006699; color:white"\|40-80%
	\|style="width: 12.5%; background: #E6FAFF; color:black"\|		\|style="width: 12.5%; background: #E6FAFF; color:black"\|20-40%
	\|style="width: 12.5%; background: #004466; color:white"\|80-100%		\|style="width: 12.5%; background: #004466; color:white"\|80-100%
	\|style="width: 12.5%; background: #004466; color:white"\|80-100%		\|style="width: 12.5%; background: #004466; color:white"\|80-100%

John at 11:19, 3 July 2023

2023-07-03T11:19:40Z

← Older revision		Revision as of 13:19, 3 July 2023
Line 43:		Line 43:
	! AML !! B ALL !! Burkitt \|\| T ALL !! ETP ALL ('''[[Early T Precursor ALL (ETP-ALL)\|i]]''') !! MPAL ('''[[Mixed Phenotype Acute Leukaemia (MPAL)\|i]]) \|\| H.gones ('''[[Haematogones\|i]]''')		! AML !! B ALL !! Burkitt \|\| T ALL !! ETP ALL ('''[[Early T Precursor ALL (ETP-ALL)\|i]]''') !! MPAL ('''[[Mixed Phenotype Acute Leukaemia (MPAL)\|i]]) \|\| H.gones ('''[[Haematogones\|i]]''')
	\|-		\|-
	\|style="width: 14.25%; background: #006699; color:white"\|40-80%		\|style="width: 12.5%; background: #006699; color:white"\|40-80%
			\|style="width: 12.5%; background: #E6FAFF; color:black"\|
	\|style="width: 12.5%; background: #004466; color:white"\|80-100%		\|style="width: 12.5%; background: #004466; color:white"\|80-100%
	\|style="width: 12.5%; background: #004466; color:white"\|80-100%		\|style="width: 12.5%; background: #004466; color:white"\|80-100%
	\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%		\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%
	\|style="width: 14.25%; background: #00b8e6; color:black"\|20-40%		\|style="width: 12.5%; background: #00b8e6; color:black"\|20-40%
	\|style="width: 14.25%; background: #00b8e6; color:black"\|20-40%		\|style="width: 12.5%; background: #00b8e6; color:black"\|20-40%
	\|style="width: 12.5%; background: #004466; color:white"\|80-100%		\|style="width: 12.5%; background: #004466; color:white"\|80-100%
	\|-		\|-

John: Created page with "
:'''Summary''' :CD200 is not lineage specific being seen in a lymphoid and myeloid disorders but has an role in diagnosis: CD200 expression aids the distinction between CLL where expression is consistent and mantle cell lymphoma (MCL) where expression is rare. It is important to realise that CD200 is not a CLL-specific marker and is also ex..."

2023-06-13T14:01:13Z

Created page with " <div style="background-color: #E0EEEE; {{round corners}} padding: 2em 2em; margin-right: 5px;"> :'''Summary''' :CD200 is not lineage specific being seen in a lymphoid and myeloid disorders but has an role in diagnosis: CD200 expression aids the distinction between CLL where expression is consistent and mantle cell lymphoma (MCL) where expression is rare. It is important to realise that CD200 is not a CLL-specific marker and is also ex..."

New page

<div style="background-color: #E0EEEE; {{round corners}} padding: 2em 2em; margin-right: 5px;">

:'''Summary'''

:CD200 is not lineage specific being seen in a lymphoid and myeloid disorders but has an role in diagnosis: CD200 expression aids the distinction between CLL where expression is consistent and mantle cell lymphoma (MCL) where expression is rare. It is important to realise that CD200 is not a CLL-specific marker and is also expressed on a wide range of other neoplastic B cell types

</div>

'''Normal expression and function'''

CD200 is a membrane glycoprotein that braodly delivers an inhibitory signal for inflammation in diverse tissues. CD200 is commonly expressed on cells of hematopoietic lineage, specifically macrophages, dendritic cells, neutrophils, mast cells and eosinophils, as well as B cells and activated T cells.

'''Diagnostic role'''

*CD200 is consisently expressed in chronic lymphocytic leukemia CLL, including cases with atypical morphology or atypical expression of other surface markers
*CD200 not usually expressed by MCL, making CD200 a particularly useful marker for discrimination between CLL and MCL. Note however that expression of MCL has been reported in a small number of cases so the distinction is not absolute
*CD200 is overexpressed by many different cell types and is neither lineage nor stage-specific, being expressed by B-cell progenitors and nearly all precursor B lymphoblastic leukemias. It is expressed by over 70% of myelomas, and hairy cell leukemia also exhibits a high level of staining
*expression in AML is also recorded

'''Other useful information'''

CD200 is also expressed on endothelial neuronal cells and cells of the reproductive organs ovaries and placental trophoblasts.

----

'''''SUMMARY TABLES'''''

{| class=wikitable style="text-align: center; font-size:80%; width: 87.5%; height 20px;"
|-
!colspan="7"|'''Expression: primitive cell types''' ''Click (i) on table for additional information'' 
|-
! AML !! B ALL !! Burkitt || T ALL !! ETP ALL ('''[[Early T Precursor ALL (ETP-ALL)|i]]''') !! MPAL ('''[[Mixed Phenotype Acute Leukaemia (MPAL)|i]]) || H.gones ('''[[Haematogones|i]]''')
|-
|style="width: 14.25%; background: #006699; color:white"|40-80%
|style="width: 12.5%; background: #004466; color:white"|80-100%
|style="width: 12.5%; background: #004466; color:white"|80-100%
|style="width: 12.5%; background: #E6FAFF; color:black"|<5%
|style="width: 14.25%; background: #00b8e6; color:black"|20-40%
|style="width: 14.25%; background: #00b8e6; color:black"|20-40%
|style="width: 12.5%; background: #004466; color:white"|80-100%
|-
|}

'''Notes:''' The main application is in AML. Aberrant expression is seen in ALL particularly in T-lineage, although it may be less likely in Burkitt lymphoma. CD117 expression can indicate MPAL or ETP-ALL if other markers are consistent.

{| class=wikitable style="text-align: center; font-size:80%; width: 100%; height 20px;"
|-
!colspan="8"|'''Expression: mature B cell neoplasms'''
|-
! CLL !! MCL !!FL!! MZL !! HCL !! DLBCL || LPL !! PCL
|-
|style="width: 12.5%; background: #004466; color:white"|80-100%
|style="width: 12.5%; background: #E6FAFF; color:black"|<5%
|style="width: 12.5%; background: #E6FAFF; color:black"|<5%
|style="width: 12.5%; background: #66e0ff; color:black"|5-20%
|style="width: 12.5%; background: #004466; color:white"|80-100%
|style="width: 12.5%; background: #66e0ff; color:black"|5-20%
|style="width: 12.5%; background: #66e0ff; color:black"|5-20%
|style="width: 14.25%; background: #006699; color:white"|40-80%
|-
|}

'''Notes:''' expression is common but selective in mature B-lymphoproliferative disorders, with expression being rare in MCL and FL

{| class=wikitable style="text-align: center; font-size:80%; width: 62.4%; height 40px;"
|-
!colspan="7"|'''Expression: mature T cell neoplasms'''
|-
! ATLL !! CTCL Sezary !! T-PLL !! T-LGL !! NK-LGL
|-
|style= "width: 20%; background: #FFE4E1; color:black"|limited
|style="width: 20%; background: #FFE4E1; color:black"|limited
|style="width: 20%; background: #FFE4E1; color:black"|limited
|style= "width: 20%; background: #FFE4E1; color:black"|limited
|style="width: 20%; background: #FFE4E1; color:black"|limited
|-
|}

'''Notes:''' limited reports are consistent with expression being uncommon in T-lymphoproliferative disorders, but expression has been described in angioimmunoblastic lymphoma
----